0000899243-18-007306.txt : 20180313
0000899243-18-007306.hdr.sgml : 20180313
20180313181116
ACCESSION NUMBER: 0000899243-18-007306
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180309
FILED AS OF DATE: 20180313
DATE AS OF CHANGE: 20180313
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fyfe Gwen A.
CENTRAL INDEX KEY: 0001506217
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33882
FILM NUMBER: 18687798
MAIL ADDRESS:
STREET 1: C/O ARRAY BIOPHARMA INC.
STREET 2: 3200 WALNUT STREET
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cascadian Therapeutics, Inc.
CENTRAL INDEX KEY: 0001412067
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 260868560
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVE.
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: (206) 801-2100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVE.
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: Oncothyreon Inc.
DATE OF NAME CHANGE: 20070927
FORMER COMPANY:
FORMER CONFORMED NAME: Biomira CORP
DATE OF NAME CHANGE: 20070911
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-09
1
0001412067
Cascadian Therapeutics, Inc.
CASC
0001506217
Fyfe Gwen A.
C/O CASCADIAN THERAPEUTICS, INC.
3101 WESTERN AVE., SUITE 600
SEATTLE
WA
98121
1
0
0
0
Common Stock
2018-03-09
4
U
0
10125
D
0
D
Restricted Stock Units
2018-03-09
4
D
0
13927
D
Common Stock
13927
0
D
Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.
The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
/s/ Julia M. Eastland (Attorney-in-Fact)
2018-03-13